S. Foulon, A. Weill, G. Maura, M. Dalichampt, M. Debouverie et al., Prévalence de la sclérose en plaques en France en 2012 et mortalité associée en 2013 à partir des données du Sniiram-PMSI, Rev DÉpidémiologie Santé Publique. 1 mars, vol.63, pp.17-25, 2015.

F. D. Lublin and S. C. Reingold, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology. avr, vol.46, issue.4, pp.907-918, 1996.

A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee et al., Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, issue.2, pp.162-73, 2018.

R. Nicholas, S. Straube, H. Schmidli, S. Pfeiffer, and T. Friede, Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis, Mult Scler Houndmills Basingstoke Engl. sept, vol.18, issue.9, pp.1290-1296, 2012.

P. S. Sorensen, S. I. Mellgren, A. Svenningsson, I. Elovaara, J. L. Frederiksen et al., NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsingremitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial, Lancet Neurol. juin, vol.8, issue.6, pp.519-548, 2009.

G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann et al., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.416-442, 2010.

J. A. Cohen, F. Barkhof, G. Comi, H. Hartung, B. O. Khatri et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-417, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617750

P. O'connor, J. S. Wolinsky, C. Confavreux, G. Comi, L. Kappos et al., Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, vol.365, issue.14, pp.1293-303, 2011.

P. S. Sorensen, J. Lycke, J. Erälinna, A. Edland, X. Wu et al., Simvastatin as add-on therapy to interferon ?-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial, Lancet Neurol. août, vol.10, issue.8, pp.691-701, 2011.

R. Gold, G. Giovannoni, K. Selmaj, E. Havrdova, X. Montalban et al., Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, doubleblind, placebo-controlled trial, Lancet Lond Engl. 22 juin, vol.381, issue.9884, pp.2167-75, 2013.

Y. C. Wang, L. Meyerson, Y. Q. Tang, and N. Qian, Statistical methods for the analysis of relapse data in MS clinical trials, J Neurol Sci, vol.15, issue.1-2, pp.206-217, 2009.

A. Jourdan and C. C. Kokonendji, Surdispersion et modèle binomial négatif généralisé, Rev Stat Appliquée, vol.50, issue.3, pp.73-86, 2002.

H. Zhu and H. Lakkis, Sample size calculation for comparing two negative binomial rates, Stat Med. 10 févr, vol.33, issue.3, pp.376-87, 2014.

A. Chan and A. Hróbjartsson, Promoting public access to clinical trial protocols: challenges and recommendations, Trials, vol.17, 2018.

Y. C. Wang, L. Meyerson, Y. Q. Tang, and N. Qian, Statistical methods for the analysis of relapse data in MS clinical trials, J Neurol Sci, vol.15, issue.1-2, pp.206-217, 2009.

H. Zhu and H. Lakkis, Sample size calculation for comparing two negative binomial rates, Stat Med. 10 févr, vol.33, issue.3, pp.376-87, 2014.

S. L. Hauser, A. Bar-or, G. Comi, G. Giovannoni, H. Hartung et al., Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.19, issue.3, pp.221-255, 2017.

R. Gold, G. Giovannoni, K. Selmaj, E. Havrdova, X. Montalban et al., Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial, Lancet Lond Engl. 22 juin, vol.381, issue.9884, pp.2167-75, 2013.

C. Confavreux, P. O'connor, G. Comi, M. S. Freedman, A. E. Miller et al., Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Neurol. mars, vol.13, issue.3, pp.247-56, 2014.

G. Comi, D. Jeffery, L. Kappos, X. Montalban, A. Boyko et al., Placebocontrolled trial of oral laquinimod for multiple sclerosis, N Engl J Med. 15 mars, vol.366, issue.11, pp.1000-1009, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00826733

L. Kappos, H. Wiendl, K. Selmaj, D. L. Arnold, E. Havrdova et al., Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.373, issue.15, pp.1418-1446, 2015.

F. D. Lublin, S. S. Cofield, G. R. Cutter, R. Conwit, P. A. Narayana et al., Randomized study combining interferon and glatiramer acetate in multiple sclerosis, Ann Neurol. mars, vol.73, issue.3, pp.327-367, 2013.

G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann et al., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.416-442, 2010.

J. A. Cohen, F. Barkhof, G. Comi, H. Hartung, B. O. Khatri et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-417, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617750

G. Comi, J. A. Cohen, D. L. Arnold, D. Wynn, M. Filippi et al., Phase III dose-comparison study of glatiramer acetate for multiple sclerosis, Ann Neurol. janv, vol.69, issue.1, pp.75-82, 2011.

O. Khan, P. Rieckmann, A. Boyko, K. Selmaj, R. Zivadinov et al., Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis, Ann Neurol. juin, vol.73, issue.6, pp.705-718, 2013.

P. S. Sorensen, S. I. Mellgren, A. Svenningsson, I. Elovaara, J. L. Frederiksen et al., NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial, Lancet Neurol. juin, vol.8, issue.6, pp.519-548, 2009.

P. S. Sorensen, J. Lycke, J. Erälinna, A. Edland, X. Wu et al., Simvastatin as add-on therapy to interferon ?-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial, Lancet Neurol. août, vol.10, issue.8, pp.691-701, 2011.

P. A. Calabresi, E. Radue, D. Goodin, D. Jeffery, K. W. Rammohan et al., Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol. juin, vol.13, issue.6, pp.545-56, 2014.

P. A. Calabresi, B. C. Kieseier, D. L. Arnold, L. J. Balcer, A. Boyko et al., Pegylated interferon ?-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study, Lancet Neurol. juill, vol.13, issue.7, pp.657-65, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01097451

R. R. Voskuhl, H. Wang, T. Wu, N. L. Sicotte, K. Nakamura et al., Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial, Lancet Neurol. janv, vol.15, issue.1, pp.35-46, 2016.

E. Havrdova, R. Zivadinov, J. Krasensky, M. G. Dwyer, I. Novakova et al., Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. août, vol.15, issue.8, pp.965-76, 2009.

L. Kappos, E. Radue, O. Connor, P. Polman, C. Hohlfeld et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.387-401, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617764

P. O'connor, J. S. Wolinsky, C. Confavreux, G. Comi, L. Kappos et al., Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, vol.365, issue.14, pp.1293-303, 2011.

R. J. Fox, D. H. Miller, J. T. Phillips, M. Hutchinson, E. Havrdova et al., Placebocontrolled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis, N Engl J Med, vol.367, issue.12, pp.1087-97, 2012.

S. Inusah, M. P. Sormani, S. S. Cofield, I. B. Aban, S. K. Musani et al., Assessing changes in relapse rates in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. déc, vol.16, issue.12, pp.1414-1435, 2010.

S. M. Steinvorth, C. Röver, S. Schneider, R. Nicholas, S. Straube et al., Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression, Mult Scler Houndmills Basingstoke Engl. oct, vol.19, issue.12, pp.1580-1586, 2013.

R. Nicholas, S. Straube, H. Schmidli, S. Pfeiffer, and T. Friede, Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis, Mult Scler Houndmills Basingstoke Engl. sept, vol.18, issue.9, pp.1290-1296, 2012.

I. Tramacere, D. Giovane, C. Salanti, G. , D. 'amico et al., Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network metaanalysis. Cochrane Database Syst Rev, p.11381, 2015.

G. Salanti, A. Nikolakopoulou, A. J. Sutton, S. Reichenbach, S. Trelle et al., Planning a future randomized clinical trial based on a network of relevant past trials, Trials. 11 juill, vol.19, issue.1, p.365, 2018.

R. Martina, D. Jenkins, S. Bujkiewicz, P. Dequen, and K. Abrams, GetReal Workpackage 1. The inclusion of real world evidence in clinical development planning, Trials. 29 août, vol.19, issue.1, p.468, 2018.

S. Lydersen, Statistical review: frequently given comments, Ann Rheum Dis. févr, vol.74, issue.2, pp.323-328, 2015.

M. P. Sormani, A. Signori, P. Siri, D. Stefano, and N. , Time to first relapse as an endpoint in multiple sclerosis clinical trials, Mult Scler Houndmills Basingstoke Engl. avr, vol.19, issue.4, pp.466-74, 2013.

T. Friede and H. Schmidli, Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials, Methods Inf Med, vol.49, issue.6, pp.618-642, 2010.

T. Friede, H. Pohlmann, and H. Schmidli, Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis, Pharm Stat, vol.18, issue.3, pp.351-65, 2019.

M. P. Sormani, P. Bruzzi, D. H. Miller, C. Gasperini, F. Barkhof et al., Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials, J Neurol Sci. 1 févr, vol.163, issue.1, pp.74-80, 1999.